Chitosan-based systems for the delivery of vaccine antigens

This review discusses the current status of chitosan and its derivatives as adjuvants and delivery systems in vaccine delivery, and their future possibilities and challenges. After a brief introduction to adjuvants and delivery systems, chitosan will be described in detail in regard to vaccine formulation. Applications of chitosan and its derivatives will be reviewed and their proposed mechanisms in the enhancement of immune responses will be discussed.

[1]  M. Garcia‐Fuentes,et al.  Nanoparticles for nasal vaccination. , 2009, Advanced drug delivery reviews.

[2]  K. Sawant,et al.  Chitosan Microparticles as Oral Delivery System for Tetanus Toxoid , 2007, Drug development and industrial pharmacy.

[3]  G. Rosenthal,et al.  Pluronic F127-based systemic vaccine delivery systems. , 2004, Vaccine.

[4]  I. Toth,et al.  Lipid and carbohydrate based adjuvant/carriers in immunology , 2003, Journal of peptide science : an official publication of the European Peptide Society.

[5]  Lisbeth Illum,et al.  Chitosan as a Novel Nasal Delivery System for Peptide Drugs , 1994, Pharmaceutical Research.

[6]  A. Osterhaus,et al.  Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses , 1984, Nature.

[7]  N. Garçon,et al.  Development and evaluation of AS04, a novel and improved adjuvant system containing MPL and aluminum salt , 2006 .

[8]  N. Mishra,et al.  Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B. , 2008, International journal of pharmaceutics.

[9]  Samir Mitragotri,et al.  Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[10]  H. Junginger,et al.  Oral drug absorption enhancement by chitosan and its derivatives. , 2001, Advanced drug delivery reviews.

[11]  S Somavarapu,et al.  Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. , 2005, Advanced drug delivery reviews.

[12]  H. Junginger,et al.  Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[13]  H. Junginger,et al.  N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model. , 2007, Vaccine.

[14]  B. Narasimhan,et al.  Vaccine adjuvants: current challenges and future approaches. , 2009, Journal of pharmaceutical sciences.

[15]  R. Rappuoli,et al.  Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan. , 2004, Vaccine.

[16]  C. Cho,et al.  The potential of mannosylated chitosan microspheres to target macrophage mannose receptors in an adjuvant-delivery system for intranasal immunization. , 2008, Biomaterials.

[17]  A. Khamesipour,et al.  The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome. , 2007, Vaccine.

[18]  H. Alpár,et al.  Comparative immunomodulatory properties of a chitosan-MDP adjuvant combination following intranasal or intramuscular immunisation. , 2005, Vaccine.

[19]  S. Xiong,et al.  Intranasal delivery of chitosan-DNA vaccine generates mucosal SIgA and anti-CVB3 protection. , 2004, Vaccine.

[20]  Wayne R. Gombotz,et al.  Protein release from alginate matrices. , 1998, Advanced drug delivery reviews.

[21]  Sanyog Jain,et al.  Chitosan nanoparticles encapsulated vesicular systems for oral immunization: preparation, in‐vitro and in‐vivo characterization , 2006, The Journal of pharmacy and pharmacology.

[22]  Maya Thanou,et al.  Trimethylated chitosans as non-viral gene delivery vectors: cytotoxicity and transfection efficiency. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[23]  Jing-jing Liu,et al.  Intranasal immunization with chitosan/pCETP nanoparticles inhibits atherosclerosis in a rabbit model of atherosclerosis. , 2008, Vaccine.

[24]  A. Vila,et al.  Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[25]  R. Muzzarelli.  Chitosan per os : from dietary supplement to drug carrier , 2000 .

[26]  E. A. Pearson,et al.  Surface modification of microspheres with steric stabilizing and cationic polymers for gene delivery. , 2008, Langmuir : the ACS journal of surfaces and colloids.

[27]  H. Onishi,et al.  Evaluation of Eudragit-coated chitosan microparticles as an oral immune delivery system. , 2005, International journal of pharmaceutics.

[28]  J. Ulmer,et al.  Microparticle-based technologies for vaccines. , 2006, Methods.

[29]  J. Schlom,et al.  Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. , 2007, Vaccine.

[30]  Manmohan J. Singh,et al.  A modified process for preparing cationic polylactide-co-glycolide microparticles with adsorbed DNA. , 2006, International journal of pharmaceutics.

[31]  B. Combadière,et al.  Particle-based vaccines for transcutaneous vaccination. , 2008, Comparative immunology, microbiology and infectious diseases.

[32]  S. Fukuyama,et al.  NALT- versus PEYER'S-patch-mediated mucosal immunity , 2004, Nature Reviews Immunology.

[33]  A. Domard,et al.  Relation between the degree of acetylation and the electrostatic properties of chitin and chitosan. , 2001, Biomacromolecules.

[34]  C. Russell Middaugh,et al.  Nanotechnology in vaccine delivery☆ , 2008, Advanced Drug Delivery Reviews.

[35]  Kozo Takayama,et al.  Novel Chitosan Particles and Chitosan-Coated Emulsions Inducing Immune Response via Intranasal Vaccine Delivery , 2004, Pharmaceutical Research.

[36]  R. Rappuoli,et al.  The concomitant use of the LTK63 mucosal adjuvant and of chitosan-based delivery system enhances the immunogenicity and efficacy of intranasally administered vaccines. , 2003, Vaccine.

[37]  N. Petrovsky.  Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity. , 2006, Vaccine.

[38]  M. S. Williams,et al.  A single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challenge. , 2008, Vaccine.

[39]  S. Davis.  The use of soluble polymers and polymer microparticles to provide improved vaccine responses after parenteral and mucosal delivery. , 2006, Vaccine.

[40]  Marie C. M. Lin,et al.  Nucleic acid delivery with chitosan and its derivatives. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[41]  H. Junginger,et al.  Preparation of coated nanoparticles for a new mucosal vaccine delivery system. , 2005, International journal of pharmaceutics.

[42]  S. Burgalassi,et al.  Effect of chitosan and of N-carboxymethylchitosan on intraocular penetration of topically applied ofloxacin. , 2004, International journal of pharmaceutics.

[43]  H. Junginger,et al.  Effect of the degree of quaternization of N-trimethyl chitosan chloride on the permeability of intestinal epithelial cells (Caco-2). , 1999, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[44]  Tushar K. Vyas,et al.  Nanocarriers for systemic and mucosal vaccine delivery. , 2007, Recent patents on drug delivery & formulation.

[45]  M. S. Williams,et al.  An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits. , 2006, Vaccine.

[46]  Manmohan J. Singh,et al.  Microparticles as vaccine adjuvants and delivery systems , 2003, Expert review of vaccines.

[47]  R. Rappuoli,et al.  Modulation of immune response to group C meningococcal conjugate vaccine given intranasally to mice together with the LTK63 mucosal adjuvant and the trimethyl chitosan delivery system. , 2004, The Journal of infectious diseases.

[48]  R. Rappuoli,et al.  Mucosal delivery of vaccines. , 1999, Methods.

[49]  K. Snibson,et al.  Pulmonary delivery of ISCOMATRIX influenza vaccine induces both systemic and mucosal immunity with antigen dose sparing , 2008, Mucosal Immunology.

[50]  I. D. de Bruijn,et al.  Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. , 2007, Vaccine.

[51]  C. Cho,et al.  Chitosan microspheres containing Bordetella bronchiseptica antigens as novel vaccine against atrophic rhinitis in pigs. , 2008, Journal of microbiology and biotechnology.

[52]  S. Davis,et al.  Chitosan as a novel nasal delivery system for vaccines. , 2001, Advanced drug delivery reviews.

[53]  D. Vanrompay,et al.  Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa. , 2006, Veterinary research.

[54]  B. Mulligan,et al.  Human vaccine research in the European Union , 2008, Vaccine.

[55]  J. Schlom,et al.  Chitosan solution enhances the immunoadjuvant properties of GM-CSF. , 2007, Vaccine.

[56]  P. Artursson,et al.  Chitosan and the mucosal delivery of biotechnology drugs. , 2005, Drug discovery today. Technologies.

[57]  A. Voigt,et al.  Polyelectrolyte complexes and layer-by-layer capsules from chitosan/chitosan sulfate. , 2002, Biomacromolecules.

[58]  Baowei Su,et al.  Interleukin-15 enhance DNA vaccine elicited mucosal and systemic immunity against foot and mouth disease virus. , 2008, Vaccine.

[59]  S. Vyas,et al.  Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally. , 2006, Vaccine.

[60]  S. Bertholet,et al.  New horizons in adjuvants for vaccine development. , 2009, Trends in immunology.

[61]  I. Azuma,et al.  Adjuvant activity of chitin derivatives in mice and guinea-pigs. , 1985, Vaccine.

[62]  N. Mishra,et al.  Surface modified liposomes for nasal delivery of DNA vaccine. , 2008, Vaccine.

[63]  H. Staats,et al.  Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination , 2007, AAPS PharmSciTech.

[64]  R. Rappuoli,et al.  A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. , 2000, Vaccine.

[65]  A. Saul,et al.  Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations. , 2005, Vaccine.

[66]  Deog-Yong Lee,et al.  Pluronic F127 enhances the effect as an adjuvant of chitosan microspheres in the intranasal delivery of Bordetella bronchiseptica antigens containing dermonecrotoxin. , 2007, Vaccine.

[67]  Tejraj M Aminabhavi,et al.  Recent advances on chitosan-based micro- and nanoparticles in drug delivery. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[68]  Sven Frokjaer,et al.  Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. , 2005, International journal of pharmaceutics.

[69]  Leaf Huang,et al.  Reactive oxygen species play a central role in the activity of cationic liposome based cancer vaccine. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[70]  G. Krivtsov,et al.  Chitosan as an adjuvant for parenterally administered inactivated influenza vaccines , 2008, Archives of Virology.

[71]  A. Almeida,et al.  Streptococcus equi antigens adsorbed onto surface modified poly-epsilon-caprolactone microspheres induce humoral and cellular specific immune responses. , 2008, Vaccine.

[72]  I. Toth,et al.  Particulate systems as adjuvants and carriers for peptide and protein antigens. , 2006, Current drug delivery.

[73]  Leaf Huang,et al.  The effects of salt on the physicochemical properties and immunogenicity of protein based vaccine formulated in cationic liposome. , 2009, International journal of pharmaceutics.

[74]  Yvonne Perrie,et al.  Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. , 2008, International journal of pharmaceutics.

[75]  S. Shin,et al.  In vivo induction of mucosal immune responses by intranasal administration of chitosan microspheres containing Bordetella bronchiseptica DNT. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[76]  Zhirong Zhang,et al.  In vitro and in vivo study of N-trimethyl chitosan nanoparticles for oral protein delivery. , 2008, International journal of pharmaceutics.

[77]  J. Robinson,et al.  Bioadhesive-based dosage forms: the next generation. , 2000, Journal of pharmaceutical sciences.

[78]  D. Cavanagh,et al.  Influenza virosomes: a flu jab for malaria? , 2008, Trends in parasitology.

[79]  P. Wertz,et al.  Enhancing effect of chitosan on peptide drug delivery across buccal mucosa. , 2000, Biomaterials.

[80]  V. Rodgers,et al.  Using TEM to couple transient protein distribution and release for PLGA microparticles for potential use as vaccine delivery vehicles. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[81]  L. Ambrosio,et al.  Chitosan-mediated stimulation of macrophage function. , 1994, Biomaterials.

[82]  R. Zinkernagel,et al.  T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[83]  S. Correa,et al.  Local and systemic activity of the polysaccharide chitosan at lymphoid tissues after oral administration , 2005, Journal of leukocyte biology.

[84]  Gerrit Borchard,et al.  Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[85]  M. Pearse,et al.  ISCOMATRIX adjuvant for antigen delivery. , 2005, Advanced drug delivery reviews.

[86]  S. Katz.  Future vaccines and a global perspective , 1997, The Lancet.

[87]  John Samuel,et al.  Biodegradable nanoparticle delivery of a Th2‐biased peptide for induction of Th1 immune responses , 2006, The Journal of pharmacy and pharmacology.

[88]  B. Liu,et al.  Enhance immune response to DNA vaccine based on a novel multicomponent supramolecular assembly , 2007, Biomaterials.

[89]  J. Irache,et al.  Experiments on a sub-unit vaccine encapsulated in microparticles and its efficacy against Brucella melitensis in mice. , 2006, Vaccine.

[90]  E. Ravichandran,et al.  Trivalent Vaccine against Botulinum Toxin Serotypes A, B, and E That Can Be Administered by the Mucosal Route , 2007, Infection and Immunity.

[91]  T. Rades,et al.  Comparison of chitosan nanoparticles and chitosan hydrogels for vaccine delivery , 2008, The Journal of pharmacy and pharmacology.

[92]  E. Thiry,et al.  Glycol chitosan improves the efficacy of intranasally administrated replication defective human adenovirus type 5 expressing glycoprotein D of bovine herpesvirus 1. , 2004, Vaccine.

[93]  Jianqing Gao,et al.  Enhanced immune responses induced by vaccine using Sendai virosomes as carrier. , 2007, International journal of pharmaceutics.

[94]  G. Pantaleo,et al.  Induction of a cytotoxic T-cell response to HIV-1 proteins with short synthetic peptides and human compatible adjuvants. , 2001, Vaccine.

[95]  Lei Jiang,et al.  Novel chitosan derivative nanoparticles enhance the immunogenicity of a DNA vaccine encoding hepatitis B virus core antigen in mice , 2007, The journal of gene medicine.

[96]  I Saiki,et al.  Immunological activity of chitin and its derivatives. , 1984, Vaccine.

[97]  S. Şenel,et al.  Potential applications of chitosan in veterinary medicine. , 2004, Advanced drug delivery reviews.

[98]  T. Polte,et al.  Vaccinations with T‐helper type 1 directing adjuvants have different suppressive effects on the development of allergen‐induced T‐helper type 2 responses , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[99]  P. Kozlowski,et al.  Mucosal vaccines: the promise and the challenge , 2006, Nature Reviews Immunology.

[100]  R. Rappuoli,et al.  Protective immune responses to meningococcal C conjugate vaccine after intranasal immunization of mice with the LTK63 mutant plus chitosan or trimethyl chitosan chloride as novel delivery platform , 2005, Journal of drug targeting.

[101]  R. Arumugham,et al.  Identification of particulates in vaccine formulations containing aluminum phosphate. , 2008, Vaccine.

[102]  P. Ogra,et al.  Vaccination Strategies for Mucosal Immune Responses , 2001, Clinical Microbiology Reviews.

[103]  Thomas Rades,et al.  Immunostimulatory colloidal delivery systems for cancer vaccines , 2006, Expert opinion on drug delivery.

[104]  S Senel,et al.  Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery. , 2008, International journal of pharmaceutics.

[105]  W. Hennink,et al.  Diphtheria toxoid-containing microparticulate powder formulations for pulmonary vaccination: preparation, characterization and evaluation in guinea pigs. , 2007, Vaccine.

[106]  R. Read,et al.  Effective nasal influenza vaccine delivery using chitosan. , 2005, Vaccine.

[107]  Lei Jiang,et al.  Augmented humoral and cellular immune responses to hepatitis B DNA vaccine adsorbed onto cationic microparticles. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[108]  C. Janeway,et al.  The Source of Early IFN-γ That Plays a Role in Th1 Priming1 , 2001, The Journal of Immunology.

[109]  R. Rappuoli,et al.  Induction of Protective Serum Meningococcal Bactericidal and Diphtheria-Neutralizing Antibodies and Mucosal Immunoglobulin A in Volunteers by Nasal Insufflations of the Neisseria meningitidis Serogroup C Polysaccharide-CRM197 Conjugate Vaccine Mixed with Chitosan , 2005, Infection and Immunity.

[110]  L. Alekseeva,et al.  Mucoadjuvant properties of lipo- and glycoconjugated derivatives of oligochitosans. , 2009, European journal of medicinal chemistry.

[111]  N. Lu,et al.  Th immune response induced by H pylori vaccine with chitosan as adjuvant and its relation to immune protection. , 2007, World journal of gastroenterology.

[112]  Balaji Narasimhan,et al.  Single dose vaccine based on biodegradable polyanhydride microspheres can modulate immune response mechanism. , 2006, Journal of biomedical materials research. Part A.